Devonian Health Group Inc (GSD) - Total Liabilities
Based on the latest financial reports, Devonian Health Group Inc (GSD) has total liabilities worth CA$1.67 Million CAD (≈ $1.21 Million USD) as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Devonian Health Group Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's total liabilities have evolved over time, based on quarterly financial data. See Devonian Health Group Inc (GSD) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Devonian Health Group Inc Competitors by Total Liabilities
The table below lists competitors of Devonian Health Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cliq Digital AG
F:CLIQ
|
Germany | €13.17 Million |
|
OB Holdings Berhad
KLSE:0327
|
Malaysia | RM14.70 Million |
|
Image Resources NL
AU:IMA
|
Australia | AU$120.74 Million |
|
GREMI MEDIA S.A. ZY 4
F:4C8
|
Germany | €46.68 Million |
|
Pion Group AB Series B
ST:PION-B
|
Sweden | Skr327.60 Million |
|
The Brand House Collective, Inc.
NASDAQ:TBHC
|
USA | $273.27 Million |
|
Rocketdna Ltd
AU:RKT
|
Australia | AU$3.53 Million |
|
Bankers Investment Trust
LSE:BNKR
|
UK | GBX134.76 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Devonian Health Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Devonian Health Group Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Devonian Health Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Devonian Health Group Inc (2015–2025)
The table below shows the annual total liabilities of Devonian Health Group Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$6.69 Million ≈ $4.84 Million |
-60.34% |
| 2024-07-31 | CA$16.87 Million ≈ $12.21 Million |
+242.26% |
| 2023-07-31 | CA$4.93 Million ≈ $3.57 Million |
-7.22% |
| 2022-07-31 | CA$5.31 Million ≈ $3.84 Million |
-25.00% |
| 2021-07-31 | CA$7.08 Million ≈ $5.12 Million |
-3.11% |
| 2020-07-31 | CA$7.31 Million ≈ $5.29 Million |
+3.41% |
| 2019-07-31 | CA$7.07 Million ≈ $5.12 Million |
+10.10% |
| 2018-07-31 | CA$6.42 Million ≈ $4.65 Million |
+90.57% |
| 2017-07-31 | CA$3.37 Million ≈ $2.44 Million |
-43.33% |
| 2016-07-31 | CA$5.95 Million ≈ $4.30 Million |
+16718.26% |
| 2016-06-30 | CA$35.36K ≈ $25.58K |
-99.46% |
| 2015-07-31 | CA$6.55 Million ≈ $4.73 Million |
-- |
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more